Abstract
Matrix metalloproteinases (MMPs) are involved in the remodeling of the extracellular matrix (ECM) in the arterial wall during atherogenesis. Collagens are the most abundant proteins in the ECM. MMP‐8 is expressed by cells associated with the development of the atherosclerotic plaque. It cleaves collagen type I three times more potently than two other interstitial collagenases MMP‐1 and MMP‐13. The aim of this study was to investigate whether plasma MMP‐8 values are associated with occurrence of carotid plaque (CP) and possible correlations with clinical and biochemical parameters in carotid atherosclerosis (CA) patients. Total plasma MMP‐8 levels were quantified by ELISA in 63 patients with ultrasonographic evidence of CP presence and 12 controls. Plasma MMP‐8 values were significantly higher in patients with CA compared with controls (median 23.36 ng/ml vs. 13.02 ng/ml, P<0.001) but they did not differ significantly according to gender, smoking and hypertensive status, associated diseases, and use of statins. Statistically significant positive correlations were observed between MMP‐8 plasma values and C reactive protein (r=0.41, P=0.001), urea (r=0.50, P<0.001), aspartate transaminase (r=0.48, P=0.001), and creatinine levels (r=0.38, P=0.006). These results suggest association of MMP‐8 plasma levels with occurrence of CP and correlation with certain biochemical markers. J. Clin. Lab. Anal. 24:246–251, 2010. © 2010 Wiley‐Liss, Inc.
Keywords: atherosclerosis, carotid plaque, collagenase, correlation, MMP‐8
REFERENCES
- 1. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005;85:1–31. [DOI] [PubMed] [Google Scholar]
- 2. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491–21494. [DOI] [PubMed] [Google Scholar]
- 3. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase‐8) in human atheroma: A novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899–1904. [DOI] [PubMed] [Google Scholar]
- 4. Hasty KA, Jeffrey JJ, Hibbs MS, Welgus HG. The collagen substrate specificity of human neutrophil collagenase. J Biol Chem 1987;262:10048–10052. [PubMed] [Google Scholar]
- 5. Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999;878:212–227. [DOI] [PubMed] [Google Scholar]
- 6. van den Borne SW, Cleutjens JP, Hanemaaijer R, et al. Increased matrix metalloproteinase‐8 and ‐9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009;18:37–43. [DOI] [PubMed] [Google Scholar]
- 7. Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP‐8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006;187:161–169. [DOI] [PubMed] [Google Scholar]
- 8. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase‐8 activity. Circulation 2004;110:337–343. [DOI] [PubMed] [Google Scholar]
- 9. Tuomainen AM, Nyyssönen K, Laukkanen JA, et al. Serum matrix metalloproteinase‐8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007;27:2722–2728. [DOI] [PubMed] [Google Scholar]
- 10. Heider P, Pelisek J, Poppert H, Eckstein HH. Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease. Vasc Endovascular Surg 2009. DOI: 10.1177/1538574409334826. [DOI] [PubMed] [Google Scholar]
- 11. Jung K. Matrix metalloproteinase‐8 and tissue inhibitor of metalloproteinase‐1 in serum do not reflect the analytes circulating in blood. Arterioscler Thromb Vasc Biol 2008;28:e15–e16. [DOI] [PubMed] [Google Scholar]
- 12. Kato R, Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Plasma matrix metalloproteinase‐8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005;69:1035–1040. [DOI] [PubMed] [Google Scholar]
- 13. Momiyama Y, Ohmori R, Tanaka N, et al. High plasma levels of matrix metalloproteinase‐8 in patients with unstable angina. Atherosclerosis 2009. DOI: 10.1016/j.atherosclerosis.2009.07.037. [DOI] [PubMed] [Google Scholar]
- 14. Belo VA, Souza‐Costa DC, Lana CM, et al. Assessment of matrix metalloproteinase (MMP)‐2, MMP‐8, MMP‐9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)‐1 and TIMP‐2 in obese children and adolescents. Clin Biochem 2009;42:984–990. [DOI] [PubMed] [Google Scholar]
- 15. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase‐8 (MMP‐8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007;379:48–52. [DOI] [PubMed] [Google Scholar]
- 16. Wyman RA, Fraizer MC, Keevil JG, et al. Ultrasound‐detected carotid plaque as a screening tool for advanced subclinical atherosclerosis. Am Heart J 2005;150:1081–1085. [DOI] [PubMed] [Google Scholar]
- 17. Krupinski J, Turu MM, Font MA, et al. Increased tissue factor, MMP‐8, and D‐dimer expression in diabetic patients with unstable advanced carotid atherosclerosis. Vasc Health Risk Manag 2007;3:405–412. [PMC free article] [PubMed] [Google Scholar]
- 18. Zhang R, Zhang YY, Huang XR, et al. C‐reactive protein promotes cardiac fibrosis and inflammation in angiotensin II‐induced hypertensive cardiac disease. Hypertension 2010;55:953–960. [DOI] [PubMed] [Google Scholar]